CAR-T and TIL cell therapy
CAR-T and TIL therapies use your own immune cells, modified or expanded in a laboratory, to fight cancer. China has several approved CAR-T products and offers them at a lower cost, often within weeks.
Who it may suit
- Lymphoma, leukaemia or myeloma that has returned or not responded to earlier treatment
- Melanoma that has progressed after standard treatment (TIL)
- Patients facing long waits or high private costs at home
What happens
- Records review and eligibility assessment
- Collection of your cells
- Manufacturing, usually 2 to 4 weeks
- Chemotherapy, infusion and close monitoring in hospital
Usually 6 to 10 weeks.
Similar therapies exist in Canada, but access is limited and private costs are high.
Things to know. Risks include cytokine release syndrome, neurological side effects and infections. Some patients need intensive care.
Why an introduction matters
Many of China’s leading specialists work in busy public hospitals without international patient offices. They rarely answer enquiries from abroad directly, and a file sent without an introduction often goes unread. Cases usually reach them through people they already know and trust. Our team on the ground makes that introduction, presents your case properly in Chinese, and follows up until you have an answer.
Some programmes, especially stem-cell and other cell treatments, are experimental. We introduce them only if you ask and your own specialist agrees, and we never describe them as cures.